{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044741","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.077475+00:00","generated_at":"2026-05-30T01:59:10.582437+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes","bullets":["Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.","Cash end Q3 $5.1M; raised $10.2M gross ($9.4M net) in Oct. private placement at $2.948/sh, 3.46M shares.","GraftAssure signed centers: ~9% German, ~2% US transplant volumes; on track for 20 centers by end of 2025.","FDA pre-sub (Q-sub) submitted for VitaGraft+ IVD; meeting scheduled early Dec.; six hospitals interested in clinical study.","Operating expenses (excl. non-cash) rose ~13% sequentially to $13.6M, driven by R&D and sales/marketing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044741","json":"https://secwatch.observer/filing/0001493152-24-044741.json","markdown":"https://secwatch.observer/filing/0001493152-24-044741.md","text":"https://secwatch.observer/filing/0001493152-24-044741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224044741/0001493152-24-044741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224044741/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:59:10.582437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}